AstraZeneca Data at WCLC Advance Ambition to Have an AstraZeneca Medicine for More Than Half of All Patients Treated for Lung Cancer by 2030
August 17, 2023
August 17, 2023
WILMINGTON, Delaware, Aug. 17 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), September 9-12, 2023.
More than 40 abstracts will feature eight approved and potential new medicines from AstraZeneca, including nine oral presentations and a late-breaking . . .
AstraZeneca advances its robust lung cancer portfolio and pipeline at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC), September 9-12, 2023.
More than 40 abstracts will feature eight approved and potential new medicines from AstraZeneca, including nine oral presentations and a late-breaking . . .